Evidence map›Paper›PMID 38140680›Full record

ArticleViruses2023

Factors Associated with Virological Failure in First-Line Antiretroviral Therapy in Patients Diagnosed with HIV-1 between 2010 and 2018 in Israel.

Tali Wagner, Itzchak Levy, Daniel Elbirt, Eduardo Shahar, Karen Olshtain-Pops, Hila Elinav, Michal Chowers, Valery Istomin, Klaris Riesenberg, Dikla Geva and 10 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 1 country.

Tali WagnerFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.
Itzchak LevyFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-4716-1293
Daniel ElbirtFaculty of Medicine, Hadassah Braun School of Public Health & Community Medicine, The Hebrew University, Jerusalem 9112102, Israel.
Eduardo ShaharImmunology Unit, Rambam Health Care Campus, Haifa 3109601, Israel.
Karen Olshtain-PopsHadassah Medical Center, Jerusalem 9112102, Israel.
Hila ElinavFaculty of Medicine, Hadassah Braun School of Public Health & Community Medicine, The Hebrew University, Jerusalem 9112102, Israel.
Michal ChowersFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0001-6148-254X
Valery IstominHillel Yaffe Medical Center, Hadera 38100, Israel.
Klaris RiesenbergGoldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba 8410501, Israel.
Dikla GevaIntegristat Ltd., Tel Aviv 69051, Israel.
Neta S ZuckermanNational HIV-1 and Viral Hepatitis Reference Laboratory, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Marina WaxNational HIV-1 and Viral Hepatitis Reference Laboratory, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Rachel ShiraziNational HIV-1 and Viral Hepatitis Reference Laboratory, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Yael GozlanNational HIV-1 and Viral Hepatitis Reference Laboratory, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Natasha MatusIchilov Medical Center, Crusaid Kobler AIDS Center, Tel Aviv 6423906, Israel.
Shirley GirshengornIchilov Medical Center, Crusaid Kobler AIDS Center, Tel Aviv 6423906, Israel.
Rotem MaromIchilov Medical Center, Crusaid Kobler AIDS Center, Tel Aviv 6423906, Israel.
Ella MendelsonFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.
Orna MorFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-3207-4226
Dan TurnerFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.
Tel Aviv University · ILSheba Medical Center · ILHebrew University of Jerusalem · ILBen-Gurion University of the Negev · ILHadassah Medical Center · ILHillel Yaffe Medical Center · ILTechnion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the progress in contemporary antiretroviral therapy (ART) and the continuous changes in treatment guidelines, virological failure (VF) is still an ongoing concern. The goal of this study was to assess factors related to VF after first-line ART. A longitudinal cohort retrospective study of individuals on first-line ART diagnosed with HIV-1 in 2010-2018 and followed-up for a median of two years was conducted. Demographics, baseline and longitudinal CD4 counts, treatment regimens, adherence and VF were recorded. The Cox proportional hazards regression and mixed models were used. A cohort of 1130 patients were included. Overall, 80% were males and 62% were Israeli-born individuals. Compared to individuals diagnosed in 2010-2014, when treatment was initiated according to CD4 levels, those diagnosed in 2015-2018 were older and had lower baseline CD4 counts. VF was recorded in 66 (5.8%) patients. Diagnosis with CD4 <200 cells/mmᶟ with AIDS-defining conditions (HR = 2.75, 95%CI:1.52-4.97,

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsHIV SeropositivityAnti-Retroviral AgentsFemaleHumansIsraelMaleRetrospective StudiesViral LoadAnti-HIV AgentsAnti-Retroviral AgentsadherenceCD4 trajectory curvesfirst-line ARTHIV-1INSTI regimenspeople living with HIV-1 (PLHIV)virological failure (VF)

Identifiers

PMID38140680
PMCPMC10748212
OpenAlexW4389780851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.